Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 19/20 | 1.00 |
| ▸ | PIK3R1 | P27986 | 12/20 | 1.00 |
| ▸ | PIK3CD | O00329 | 5/20 | 1.00 |
| ▸ | PIK3CB | P42338 | 5/20 | 1.00 |
| ▸ | RAF1 | P04049 | 1/20 | 1.00 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.51 |
| ▸ | MTOR | P42345 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16612097 | 0.95 | PIK3CA (0.90) | PIK3CAPIK3R1PIK3CDPIK3CBRAF1 | |
| SCHEMBL16622897 | 0.94 | PIK3CA (1.00) | PIK3CAPIK3R1PIK3CDPIK3CBRAF1 | |
| SCHEMBL16611536 | 0.93 | PIK3CA (0.87) | PIK3CAPIK3R1PIK3CDPIK3CBRAF1 | |
| SCHEMBL16612094 | 0.93 | PIK3CA (0.86) | PIK3CAPIK3R1PIK3CDPIK3CBRAF1 | |
| SCHEMBL16622896 | 0.92 | PIK3CA (1.00) | PIK3CAPIK3R1PIK3CDPIK3CBRAF1 | |
| SCHEMBL16727846 | 0.92 | PIK3CA (0.85) | PIK3CAPIK3R1PIK3CDPIK3CBRAF1 | |
| SCHEMBL16611467 | 0.91 | PIK3CA (1.00) | PIK3CAPIK3R1PIK3CDPIK3CBRAF1 | |
| SCHEMBL18357171 | 0.90 | PIK3CA (0.82) | PIK3CAPIK3R1PIK3CDPIK3CBRAF1 | |
| SCHEMBL26134608 | 0.90 | PIK3CA (0.82) | PIK3CAPIK3R1PIK3CDPIK3CBRAF1 | |
| SCHEMBL16610959 | 0.90 | PIK3CA (0.99) | PIK3CAPIK3R1PIK3CDPIK3CBRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4704841-A1 | IMLUNESTRANT OR SALTS THEREOF FOR USE IN TREATING AND PREVENTING CENTRAL NERVOUS SYSTEM (CNS) METASTASES IN SUBJECTS HAVING ER+ BREAST CANCER | Eli Lilly and Company (US) | 2026-03-11 | — | — | EP | claimed |
| US-20260060969-A1 | METHODS FOR THE TREATMENT OF LYMPHOPROLIFERATIVE DISORDERS | INST NAT SANTE RECH MED (FR) | 2026-03-05 | — | — | US | claimed |
| US-20260000658-A1 | METHODS FOR THE TREATMENT OF PROLIFERATIVE GLOMERULONEPHRITIS | INST NAT SANTE RECH MED (FR) | 2026-01-01 | — | — | US | claimed |
| EP-4565217-A1 | METHODS FOR THE TREATMENT OF LYMPHOPROLIFERATIVE DISORDERS | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-06-11 | — | — | EP | claimed |
| CN-118987015-A | Application of antisense oligonucleotide in preparation of medicine for treating breast cancer | 北京悦康科创医药科技股份有限公司 | 2024-11-22 | — | — | CN | claimed |
| WO-2024233256-A1 | IMLUNESTRANT OR SALTS THEREOF FOR USE IN TREATING AND PREVENTING CENTRAL NERVOUS SYSTEM (CNS) METASTASES IN SUBJECTS HAVING ER+ BREAST CANCER | ELI LILLY AND COMPANY (US) | 2024-11-14 | — | — | WO | claimed |
| US-20240294876-A1 | METHODS FOR THE EXPANSION OF HUMAN GRANULOCYTE-MACROPHAGE PROGENITORS AND APPLICATIONS THEREOF | UNIV SOUTHERN CALIFORNIA (US) | 2024-09-05 | — | — | US | claimed |
| CN-118119383-A | Pharmaceutical combinations comprising PI3K alpha inhibitors | 上海海和药物研究开发股份有限公司 | 2024-05-31 | — | — | CN | claimed |
| EP-4341386-A2 | METHODS FOR THE EXPANSION OF HUMAN GRANULOCYTEMACROPHAGE PROGENITORS AND APPLICATIONS THEREOF | University of Southern California (US) | 2024-03-27 | — | — | EP | claimed |
| CN-117751182-A | Method for amplifying human granulocyte-macrophage progenitor cells and application thereof | 南加利福尼亚大学 | 2024-03-22 | — | — | CN | claimed |
| CN-117717565-A | Application of antisense oligonucleotide in preparing medicament for treating esophagus cancer | 北京悦康科创医药科技股份有限公司 | 2024-03-19 | — | — | CN | claimed |
| WO-2024028433-A1 | METHODS FOR THE TREATMENT OF LYMPHOPROLIFERATIVE DISORDERS | Institut National de la Santé et de la Recherche Médicale (FR) | 2024-02-08 | — | — | WO | claimed |
| WO-2024015527-A1 | THERAPEUTIC COMBINATIONS OF DRUGS, COMPANION DIAGNOSTICS AND METHODS FOR DOSAGING AND USING THEM | BAYESIAN BIOTECH, LLC (US) | 2024-01-18 | — | — | WO | claimed |
| WO-2024011307-A1 | PYRAZOLO[3,4-D]PYRIMIDIN-6-YL-SULFONAMIDE DERIVATIVES FOR THE INHIBITION OF SGK-1 AND TREATMENT OF CANCER | THRYV THERAPEUTICS INC. (CA) | 2024-01-18 | — | — | WO | claimed |
| WO-2023035614-A1 | DRUG COMBINATION CONTAINING PI3Kα INHIBITOR | 上海海和药物研究开发股份有限公司 | 2023-03-16 | — | — | WO | claimed |
| WO-2023285681-A1 | PHARMACEUTICAL COMBINATIONS FOR TREATING CANCER | SPEXIS AG (CH) | 2023-01-19 | — | — | WO | claimed |
| WO-2022245977-A2 | METHODS FOR THE EXPANSION OF HUMAN GRANULOCYTEMACROPHAGE PROGENITORS AND APPLICATIONS THEREOF | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2022-11-24 | — | — | WO | claimed |
| US-20260146050-A1 | KRAS DEGRADING COMPOUNDS COMPRISING SPIROCYCLIC ANNULATED 2 AMINO-3-CYANO THIOPHENES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2026-05-28 | — | — | US | disclosed |
| US-20150141644-A1 | PYRROLO[2,1-F][1,2,4]TRIAZINE COMPOUND, AND PREPARATION METHOD AND APPLICATION THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2015-05-21 | — | — | US | disclosed |
| EP-2857403-A1 | PYRROLO[2,1-F][1,2,4]TRIAZINE COMPOUND, AND PREPARATION METHOD AND APPLICATION THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2015-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141644-A1 | PYRROLO[2,1-F][1,2,4]TRIAZINE COMPOUND, AND PREPARATION METHOD AND APPLICATION THEREOF | PIK3CA, PIK3R5, PIP4K2B | PIK3CA 1/4885PIK3R1 18/4885PIK3CD 4/4885 |
| US-20260146050-A1 | KRAS DEGRADING COMPOUNDS COMPRISING SPIROCYCLIC ANNULATED 2 AMINO-3-CYANO THIOPHENES | KRAS, NRAS, HRAS | PIK3CA 177/4885PIK3R1 1291/4885PIK3CD 712/4885 |
| US-20260000658-A1 | METHODS FOR THE TREATMENT OF PROLIFERATIVE GLOMERULONEPHRITIS | PIK3R4, PIK3CA, PIK3R5 | PIK3CA 2/4885PIK3R1 4/4885PIK3CD 8/4885 |
| US-20260060969-A1 | METHODS FOR THE TREATMENT OF LYMPHOPROLIFERATIVE DISORDERS | PIK3R4, PIK3R5, PIK3R1 | PIK3CA 7/4885PIK3R1 3/4885PIK3CD 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.